Citigroup’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.82M Buy
5,646
+60
+1% +$18.6K ﹤0.01% 2721
2025
Q4
$1.65M Buy
5,586
+2,779
+99% +$518K ﹤0.01% 2785
2025
Q3
$149K Sell
2,807
-9,059
-76% -$439K ﹤0.01% 4117
2025
Q2
$499K Sell
11,866
-33,766
-74% -$1.29M ﹤0.01% 3629
2025
Q1
$1.73M Sell
45,632
-49,415
-52% -$3.09M ﹤0.01% 2829
2024
Q4
$7.31M Buy
95,047
+11,697
+14% +$846K ﹤0.01% 1623
2024
Q3
$4.8M Buy
83,350
+75,739
+995% +$4.09M ﹤0.01% 1884
2024
Q2
$315K Sell
7,611
-7,507
-50% -$355K ﹤0.01% 3661
2024
Q1
$923K Sell
15,118
-8,406
-36% -$377K ﹤0.01% 3093
2023
Q4
$524K Buy
23,524
+17,983
+325% +$324K ﹤0.01% 3376
2023
Q3
$142K Buy
5,541
+5,529
+46,075% +$105K ﹤0.01% 3809
2023
Q2
$214 Sell
12
-107
-90% -$1.64K ﹤0.01% 5427
2023
Q1
$1.45K Sell
119
-18
-13% -$760 ﹤0.01% 5127
2022
Q4
$4.89K Sell
137
-495
-78% -$15.4K ﹤0.01% 5035
2022
Q3
$22K Sell
632
-15,606
-96% -$778K ﹤0.01% 4715
2022
Q2
$597K Buy
16,238
+14,219
+704% +$1.52M ﹤0.01% 3077
2022
Q1
$309K Sell
2,019
-3,359
-62% -$690K ﹤0.01% 3828
2021
Q4
$1.59M Buy
5,378
+2,837
+112% +$832K ﹤0.01% 2806
2021
Q3
$705K Buy
2,541
+81
+3% +$22K ﹤0.01% 3366
2021
Q2
$674K Sell
2,460
-652
-21% -$233K ﹤0.01% 3496
2021
Q1
$1.53M Buy
3,112
+2,966
+2,032% +$2.11M ﹤0.01% 2676
2020
Q4
$120K Buy
+146
New +$85.2K ﹤0.01% 5395

Other funds holding PRAX

Citigroup's PRAX Position: Q1 2026 in Review

Citigroup increased its Praxis Precision Medicines (PRAX) stake by 1.1% in Q1 2026, buying an estimated $18.6K and bringing the position to 5,646 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Citigroup first reported a position in PRAX in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.31M in Q4 2024. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Citigroup held 5,646 shares of Praxis Precision Medicines worth $1.82M as of Q1 2026.
  • Citigroup bought 60 Praxis Precision Medicines shares in Q1 2026, an estimated $18.6K.
  • Praxis Precision Medicines made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2721 holding.
  • Citigroup first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Praxis Precision Medicines position peaked at $7.31M in Q4 2024.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.